{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["167(2)"],"submitter":["Rogers JL"],"pubmed_abstract":["<h4>Purpose</h4>Multidisciplinary tumor boards (MTBs) integrate clinical, molecular, and radiological information and facilitate coordination of neuro-oncology care. During the COVID-19 pandemic, our MTB transitioned to a virtual and multi-institutional format. We hypothesized that this expansion would allow expert review of challenging neuro-oncology cases and contribute to the care of patients with limited access to specialized centers.<h4>Methods</h4>We retrospectively reviewed records from virtual MTBs held between 04/2020-03/2021. Data collected included measures of potential clinical impact, including referrals to observational or therapeutic studies, referrals for specialized neuropathology analysis, and whether molecular findings led to a change in diagnosis and/or guided management suggestions.<h4>Results</h4>During 25 meetings, 32 presenters discussed 44 cases. Approximately half (n = 20; 48%) involved a rare central nervous system (CNS) tumor. In 21% (n = 9) the diagnosis was changed or refined based on molecular profiling obtained at the NIH and in 36% (n = 15) molecular findings guided management. Clinical trial suggestions were offered to 31% (n = 13), enrollment in the observational NCI Natural History Study to 21% (n = 9), neuropathology review and molecular testing at the NIH to 17% (n = 7), and all received management suggestions.<h4>Conclusion</h4>Virtual multi-institutional MTBs enable remote expert review of CNS tumors. We propose them as a strategy to facilitate expert opinions from specialized centers, especially for rare CNS tumors, helping mitigate geographic barriers to patient care and serving as a pre-screening tool for studies. Advanced molecular testing is key to obtaining a precise diagnosis, discovering potentially actionable targets, and guiding management."],"journal":["Journal of neuro-oncology"],"pagination":["349-359"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11023967"],"repository":["biostudies-literature"],"pubmed_title":["Virtual multi-institutional tumor board: a strategy for personalized diagnoses and management of rare CNS tumors."],"pmcid":["PMC11023967"],"pubmed_authors":["Quezado MM","Theeler BJ","Widemann BC","Boris L","Camphausen KA","Snyder J","Armstrong TS","Chaudhry H","Forsyth P","Salacz ME","Smirniotopoulos JG","Drappatz J","Lee EQ","Aboud O","Gilbert MR","Ozer BH","Zaghloul K","Smith-Cohn MA","Aldape K","Raygada M","Wall T","Penas-Prado M","Rogers JL","Lukas RV","Mandel J","Dixit KS","Soldatos A","Tsien CI","Heiss JD","Butman JA","Chittiboina P","Acquaye-Mallory AA","Dunbar EM","Avgeropoulos NG","Kim Y","Komlodi-Pasztor E","Cachia DM","Ranjan S","Burton EC"],"additional_accession":[]},"is_claimable":false,"name":"Virtual multi-institutional tumor board: a strategy for personalized diagnoses and management of rare CNS tumors.","description":"<h4>Purpose</h4>Multidisciplinary tumor boards (MTBs) integrate clinical, molecular, and radiological information and facilitate coordination of neuro-oncology care. During the COVID-19 pandemic, our MTB transitioned to a virtual and multi-institutional format. We hypothesized that this expansion would allow expert review of challenging neuro-oncology cases and contribute to the care of patients with limited access to specialized centers.<h4>Methods</h4>We retrospectively reviewed records from virtual MTBs held between 04/2020-03/2021. Data collected included measures of potential clinical impact, including referrals to observational or therapeutic studies, referrals for specialized neuropathology analysis, and whether molecular findings led to a change in diagnosis and/or guided management suggestions.<h4>Results</h4>During 25 meetings, 32 presenters discussed 44 cases. Approximately half (n = 20; 48%) involved a rare central nervous system (CNS) tumor. In 21% (n = 9) the diagnosis was changed or refined based on molecular profiling obtained at the NIH and in 36% (n = 15) molecular findings guided management. Clinical trial suggestions were offered to 31% (n = 13), enrollment in the observational NCI Natural History Study to 21% (n = 9), neuropathology review and molecular testing at the NIH to 17% (n = 7), and all received management suggestions.<h4>Conclusion</h4>Virtual multi-institutional MTBs enable remote expert review of CNS tumors. We propose them as a strategy to facilitate expert opinions from specialized centers, especially for rare CNS tumors, helping mitigate geographic barriers to patient care and serving as a pre-screening tool for studies. Advanced molecular testing is key to obtaining a precise diagnosis, discovering potentially actionable targets, and guiding management.","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Apr","modification":"2026-05-29T12:38:32.342Z","creation":"2026-04-08T04:46:44.817Z"},"accession":"S-EPMC11023967","cross_references":{"pubmed":["38427131"],"doi":["10.1007/s11060-024-04613-6"]}}